v3.26.1
Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)
Mar. 31, 2026
Dec. 31, 2025
Schedule of Accrued Expenses and Other Current Liabilities [Abstract]    
Accrued research and development expense [1] $ 1,741,083 $ 1,754,083
Accrued directors and officers (owners) compensation 1,358,037 1,358,293
Cash portion of the Lind Note repayments 500,000 492,376
Accrued compensation and employee benefits 31,391 86,744
Others 523,853 470,133
Total $ 4,154,364 $ 4,161,629
[1] Accrued research and development expense represents the amount due to outside contracted services for manufacturing and process development.